



Press Contact :
NEORPHYS
Valérie MERCHEZ
Tél. : +33 (0)4 66 02 18 10
vmerchez@neorphys.com

**NEORPHYS,
the French biopharmaceutical company focussed on lifestyle drugs,
closes its first fund raising to accelerate its development.**

INSERM TRANSFERT INITIATIVE and SORIDEC take part in this first financing round.

Nîmes (France), April 5th, 2007 - NEORPHYS, a young biopharmaceutical company based in Nîmes (France), that discovers and develops proprietary lifestyle drug candidates, announces today the closing of a € 300 000 financing round, aimed at accelerating the preclinical development of its current programs. Two well established investors, INSERM TRANSFERT INITIATIVE and SORIDEC, took part in this seed financing round.

In addition to the Founders' own resources, this round will enable the company to initiate the regulatory preclinical development of a drug candidate in the field of pain. In parallel, Neorphys will develop its second axis of research in the field of female desire dysfunction.

NEORPHYS innovative approach:

Currently, opioid drugs are still the drugs of choice for acute pain, starting with morphine itself which is used in 70% of the cases despite its numerous drawbacks (nausea, respiratory depression and, most of all, severe constipation and addiction). The unmet need in acute pain management is not to get a more active drug than morphine but one with lower side effects at equipotent doses. The total market for pain is about €20 billion per year.

As of today, several novel orally active opioids, the Neorphines™, have been designed, synthesised and validated in animal models by Neorphys scientists. A first patent was filed on October 2006, 12th (FR-06/54247). Compared with morphine at equivalent doses, Neorphines™ main therapeutical benefits, in animal models, include higher activity, a 10- to 12-fold longer duration of action and a return to normal gastro-intestinal transit within the analgesic coverage.

All these characteristics, when combined, open a potential field of application for Neorphines™ both in acute and chronic pain. Neorphys intends to develop the most relevant molecules up to phase 2.

"This first round is a major stage of our development" said Dr Roger Lahana, CEO of Neorphys. "Our axes of research have received the financing support that we need to bring our best lead through regulatory phases in a very short period of time. This recognition by a number of prestigious VCs, who have audited our business plan, also constitutes an important external validation".

About NEORPHYS:

Founded in September 2005, NEORPHYS is a biopharmaceutical company focused on lifestyle drugs. Research and development efforts target novel proprietary drug candidates in the field of pain and in the field of female desire dysfunction.

NEORPHYS founders are Roger LAHANA (CEO) and Karine LARBOURET (Director of Operations). The team includes 6 people. The company is located in Nîmes (France) on the campus of the University of Medicine.

More information is available on www.neorphys.com

About INSERM-TRANSFERT INITIATIVE:

Inserm-Transfert Initiative is a venture capital company with a € 4.2 M fund, focussed on seed financing in the biomedical field. Inserm-Transfert Initiative associates four actors in the financing of biotech start-up: Inserm-Transfert SA, CDC Entreprises, Ventech and Sofinnova Partners. Inserm-Transfert Initiative supports biotech company creators in their early stages.

More information is available on www.it-initiative.fr

About SORIDEC:

Soridec is a Languedoc-Roussillon investment capital company with a mixed public/private capital of € 22 M. Its general vocation enables it to take interest in all types of projects (biotechnology, information technology, industry, industrial services). Soridec is in position to bring financing support at any stage of a company's life. Considering the expressed needs over the last three years, Soridec has strongly acted on segments of small company seed and small company creation or transmission. On December 31st, 2006, Soridec portfolio amounted to € 16 M, invested in about 80 companies.

More information is available on www.soridec.fr